The effect of desmopressin acetate on postoperative hemorrhage in patients receiving aspirin therapy before coronary artery bypass operations.

Gratz I, Koehler J, Olsen D, Afshar M, DeCastro N, Spagna PM, Ablaza SG, Larijani GE

The Journal of thoracic and cardiovascular surgery1 Nov 1992Cited by 48 (Europe PMC)

PMID1434725DOI10.1016/s0022-5223(19)34638-0PepBankPUB-01434725

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

01HumanRandomized controlled trialEfficacy outcome
In aspirin-pretreated coronary bypass patients, desmopressin reduced chest tube blood loss versus placebo.
In plain wordsIn aspirin-pretreated coronary bypass patients, desmopressin reduced chest tube blood loss versus placebo.
Peptide
Desmopressin
Outcome
DecreaseChest tube blood loss
Study
n = 65
Comparator
Placebo
Outcome group
Bleeding and clotting · Cardiovascular
Studied dose
0.3 micrograms/kgAs given in this study (human).
Measurements
Chest tube blood loss
833 ml
desmopressin, +/- 311
Chest tube blood loss
1176 ml
placebo, +/- 674
p
0.016
between groups
Source sentences
Summary
There was a significant reduction in postoperative blood loss noted between groups for both chest tube blood loss (833 +/- 311 ml for the 1-desamino-8-D-arginine vasopressin [desmopressin] group versus 1176 +/- 674 ml for the placebo group; p = 0.016)
2 context sentences(design, population, supporting numbers)
Summary · context
We conducted a prospective, randomized, placebo-controlled, double-blind trial to determine the effectiveness and safety of desmopressin in these patients.
Summary · context
Sixty-five patients pretreated with aspirin within 7 days before their scheduled elective coronary artery bypass grafting were randomized to receive desmopressin (0.3 micrograms/kg) or placebo after cessation of bypass and reversal of heparin with protamine.
Report a problemFND-0143472501
02HumanRandomized controlled trialEfficacy outcome
In aspirin-pretreated coronary bypass patients, desmopressin reduced total blood loss versus placebo.
In plain wordsIn aspirin-pretreated coronary bypass patients, desmopressin reduced total blood loss versus placebo.
Peptide
Desmopressin
Outcome
DecreaseTotal blood loss
Study
n = 65
Comparator
Placebo
Outcome group
Bleeding and clotting · Cardiovascular
Studied dose
0.3 micrograms/kgAs given in this study (human).
Measurements
Total blood loss
1215 ml
desmopressin, +/- 381
Total blood loss
1637 ml
placebo, +/- 761
p
0.0097
between groups
Source sentences
Summary
total blood loss (1215 +/- 381 ml for the desmopressin group versus 1637 +/- 761 ml for the placebo group; p = 0.0097).
2 context sentences(design, population, supporting numbers)
Summary · context
We conducted a prospective, randomized, placebo-controlled, double-blind trial to determine the effectiveness and safety of desmopressin in these patients.
Summary · context
Sixty-five patients pretreated with aspirin within 7 days before their scheduled elective coronary artery bypass grafting were randomized to receive desmopressin (0.3 micrograms/kg) or placebo after cessation of bypass and reversal of heparin with protamine.
Report a problemFND-0143472502
03HumanRandomized controlled trialEfficacy outcome
In aspirin-pretreated coronary bypass patients, red cell transfusions did not differ significantly between desmopressin and placebo.
In plain wordsIn aspirin-pretreated coronary bypass patients, red cell transfusions did not differ significantly between desmopressin and placebo.
Peptide
Desmopressin
Outcome
No significant changeRed cell transfusions
Study
n = 65
Comparator
Placebo
Outcome group
Bleeding and clotting · Cardiovascular
Studied dose
0.3 micrograms/kgAs given in this study (human).
Source sentences
Summary
Despite the differences in blood loss between the two groups, the red cell transfusions were not significantly different, but the use of platelets was less in the desmopressin group and almost achieved statistical significance (p = 0.053).
2 context sentences(design, population, supporting numbers)
Summary · context
We conducted a prospective, randomized, placebo-controlled, double-blind trial to determine the effectiveness and safety of desmopressin in these patients.
Summary · context
Sixty-five patients pretreated with aspirin within 7 days before their scheduled elective coronary artery bypass grafting were randomized to receive desmopressin (0.3 micrograms/kg) or placebo after cessation of bypass and reversal of heparin with protamine.
Report a problemFND-0143472503
04HumanRandomized controlled trialEfficacy outcome
In aspirin-pretreated coronary bypass patients, platelet use was lower with desmopressin than placebo but did not reach statistical significance.
In plain wordsIn aspirin-pretreated coronary bypass patients, platelet use was lower with desmopressin than placebo, without statistical significance.
Peptide
Desmopressin
Outcome
No significant changePlatelet use
Study
n = 65
Comparator
Placebo
Outcome group
Bleeding and clotting · Cardiovascular
Studied dose
0.3 micrograms/kgAs given in this study (human).
Measurements
p
0.053
platelet use
Source sentences
Summary
Despite the differences in blood loss between the two groups, the red cell transfusions were not significantly different, but the use of platelets was less in the desmopressin group and almost achieved statistical significance (p = 0.053).
2 context sentences(design, population, supporting numbers)
Summary · context
We conducted a prospective, randomized, placebo-controlled, double-blind trial to determine the effectiveness and safety of desmopressin in these patients.
Summary · context
Sixty-five patients pretreated with aspirin within 7 days before their scheduled elective coronary artery bypass grafting were randomized to receive desmopressin (0.3 micrograms/kg) or placebo after cessation of bypass and reversal of heparin with protamine.
Report a problemFND-0143472504
05HumanRandomized controlled trialSafety outcome
In aspirin-pretreated coronary bypass patients, thrombotic complications did not differ between desmopressin and placebo.
In plain wordsIn aspirin-pretreated coronary bypass patients, thrombotic complications did not differ between desmopressin and placebo.
Peptide
Desmopressin
Outcome
No significant changeThrombotic complications
Study
n = 65
Comparator
Placebo
Outcome group
Cardiovascular events · Cardiovascular
Studied dose
0.3 micrograms/kgAs given in this study (human).
Source sentences
Summary
Neither was there a difference in the occurrence of thrombotic complications between groups.
2 context sentences(design, population, supporting numbers)
Summary · context
We conducted a prospective, randomized, placebo-controlled, double-blind trial to determine the effectiveness and safety of desmopressin in these patients.
Summary · context
Sixty-five patients pretreated with aspirin within 7 days before their scheduled elective coronary artery bypass grafting were randomized to receive desmopressin (0.3 micrograms/kg) or placebo after cessation of bypass and reversal of heparin with protamine.
Report a problemFND-0143472505

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:35 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.